IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
March 20 2024 - 6:02AM
Business Wire
Significant throughput of LSA to advance
IPA’s diversity- and data-driven drug development and to enrich
LENSai™.
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an artificial intelligence-driven biotherapeutic
research and technology company, today announced that it has
acquired the LSA® instrument platform from Carterra®, a leading
provider of high-throughput large and small molecule screening and
characterization solutions. This instrument allows for high
throughput surface plasmon resonance-based antibody
characterizations thereby significantly increasing the Company’s
capacity in performing various label-free protein interaction
analyses including best-in-class kinetics, epitope binning,
quantitation, epitope mapping, and blocking/neutralization
assays.
IPA remains committed to expanding its contract research
organization (CRO) capabilities and leveraging technology to drive
innovation and efficiency, particularly in AI-driven drug design.
Carterra’s LSA instrument delivers significant throughput in short
time frames requiring only small sample volumes. This fits well
with the company’s established high throughput capabilities and
diversity- and data-driven drug discovery, delivering huge amounts
of valuable data points at an early-stage to advance the lead
triaging process. The efficiency gain resulting from the
acquisition will not only expedite the Company’s in vitro
characterizations for clients and partners, but also rapidly fuels
LENSai with valuable data sets to optimize models for next gen in
silico drug discovery and development utilizing their proprietary
HYFTs to aggregate and integrate biological data.
“The significance of our LENSai technology extends beyond just
the creation of an advanced tool,” says IPA’s Chief Executive
Officer and President, Jennifer Bath, PhD. “It represents a
strategic move to capture the growing interest in and huge
potential of AI-driven drug discovery and digital biology.
Complementing our well-established high throughput antibody
discovery, production, and screening capabilities, Carterra’s LSA
gets us closer to making ours the fastest and most cost-effective
drug discovery workflow.”
“We couldn’t be more excited to join with IPA in changing the
way drugs are discovered,” said Tim Germann, Chief Commercial
Officer at Carterra. “The LSA has made the use of AI in antibody
discovery a reality; nothing generates more data in as little time
to train AI/ML engines.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR
technology provides large-molecule and small-molecule drug
discovery customers with screening and characterization throughput
and functionality that scales with omics-level applications,
condensing months of work down to days. Our solutions have enabled
multiple therapeutics and breakthrough research and helped academic
and translational researchers and biopharmaceutical companies in
oncology, immunology, neuroscience, and more. Carterra is based in
Salt Lake City, Utah, and has Customer Experience Centers in San
Francisco, Salt Lake City, Boston, Manchester, England, and Munich,
Germany. Carterra products are available in Asia-Pacific and
Oceania through our exclusive distributor, Revvity. To learn more,
visit www.carterra-bio.com or connect with us on LinkedIn or X
(Twitter).
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, and statements relating to IPA’s expected
increased revenue streams and financial growth. In respect of the
forward-looking information contained herein, IPA has provided such
statements and information in reliance on certain assumptions that
management believed to be reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the expected healthcare benefits
including lowering development timeliness, and costs and that
development of targeted treatments will not be achieved, in
addition actual results could differ materially from those
currently anticipated due to a number of factors and risks, as
discussed in the Company’s Annual Information Form dated July 10,
2023 (which may be viewed on the Company’s profile at
www.sedar.com), and the Company’s Form 40-F, dated July 10, 2023
(which may be viewed on the Company’s profile at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. Accordingly, readers
should not place undue reliance on forward-looking information
contained in this news release. The forward-looking statements
contained in this news release are made as of the date of this
release and, accordingly, are subject to change after such date.
The Company does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320099936/en/
IPA: info@ipatherapeutics.com
Carterra: Cheri Salazar Sr. Marketing Manager +1
(408) 594-9400
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From May 2023 to May 2024